Insights Accelerated
40 Years On: What the Ludwig Institute in Uppsala Teaches Us About Building Science
In 1984, a young Japanese doctor walked up to a Swedish lecturer in Tokyo and asked to join his lab. Forty years later, he was among 140 alumni who returned to Uppsala to celebrate the Ludwig Institute. We look at how Calle Heldin's lab trained leaders on three continents, and what it means for the future of cancer research.
What the Science Needs Next
Pelago Bioscience began with a method invented at Karolinska Institutet. Its growth into a drug discovery partner spanning biology and chemistry suggests that a founder’s work is not only to prove the science, but to keep finding the expertise that carries it further.
Executive Ventures launches with Carolina Ragnerstam as CEO
Executive Ventures AB today announced the appointment of Carolina Ragnerstam as Chief Executive Officer. Executive Ventures is a life science executive search, interim leadership and board advisory firm, and the sister company to Ventures Accelerated AB, founded by Helena Strigård.
Cancer Vaccines, no longer science fiction
After two decades as the idea that never quite worked, the personalised cancer vaccine has cut melanoma recurrence by 49 per cent in Phase 3. Researchers, a founder and an investor unpack what changed, what it will cost and which tumours come next. Read the full article.
Introducing Capital Insights – Money Talks with the Investor Community
Why has the fixed-dose pill survived for nearly two centuries? In the first episode of Capital Insights, our new podcast, OnDosis CEO Martin Olovsson explains how precision dosing could become pharma's biggest untapped opportunity, and what it takes to cross the Atlantic. Read the article, and listen Capital Insights on Spotify.
Down the Biotech Rabbit Hole
Capital is back, but the door is narrower. Through an Alice in Wonderland lens, this article shows why investors are slashing burn rates, why partnering feels like a Mad Tea Party, and how to make the improbable credible. Follow the white rabbit and read the full article.
Meet our Accelerators - Patricia Beckmann
From Uppsala postdoc to co-inventor of the blockbuster drug Enbrel — Patricia Beckmann's career has been anything but a straight line. In this interview, she reflects on lessons learned from failures and shelved successes, and why she believes a Seattle–Sweden life science exchange could propel both ecosystems forward.
At BIO 2026, partnerships moved beyond the deal.
Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.
The Crown Jewel Test
Why did fewer meetings at BIO 2026 deliver more than a packed calendar ever did? In a recent interview AOP Health's Eszter Kormann shares her "crown jewel" philosophy of sourcing — why fair beats cheap, what happens after the signature, and why the scarcest resource in dealmaking is conviction.
New Players Are Reshaping Life Science Financing
A recent pitch night hosted by Cancerfonden together with VILDA offered a glimpse of a broader shift taking place in life science financing.
Backtracking from the Endgame
AnaCardio is using its CEO’s experience on both sides of pharma partnering to shape a global Phase 2b for AC01, its oral treatment candidate for heart failure.
The Conversations That Keep Going
What makes some conversations continue long after a conference ends — and even turn into signed deals within weeks? Venture Road's journeys through California, Stockholm and the UK reveal what happens when the right people actually meet. Next stop: Venture Bridge during Nobel Week. Read on to find out why participants keep coming back.
Biotech Conference Approaching - Should I fill up my Dance Card?
Is your partnering conference calendar full — or full of the right meetings? This witty take on biotech business development weighs precision matchmaking against speed-dating-style volume, and lands on a smarter third way. Before you book another dance card, read this article.
Meet our accelerators: Ragnar Strigård & Njord
Recent interview with Ragnar Strigård explores how his accelerator model helps life science founders transform high‑potential research into fundable, scalable companies.
Beyond the Science: Decoding the "Globally Street Smart" Approach to Negotiation
In a recent interview, Helena shared her perspective on why authenticity, a tolerance for friction, and the ability to "read the room" from a macro perspective are the tools to thrive in negotiations.
The Hard Middle of Biotech
Insights Accelerated was among just 200 accredited press outlets at this year’s BIO, where capital felt scarcer, more selective, and more global — and investors’ questions moved earlier in the development timeline. Here is a pulse check from San Diego, across five companies working the gap between promise and proof.
Strategic Partnership: Iconovo’s Long-Term Collaboration with Lonza
How does a small inhalation specialist become a trusted global player? Iconovo’s Anders Månsson shares why deep, strategic partnerships with leaders like Lonza can transform both technology access and investor confidence.
Driven by Purpose: Voices from the Swedish Pavilion at BIO International 2026
As this year’s BIO International Convention embraced the theme Driven by Purpose, Ventures Accelerated sent a flying reporter to the Swedish Pavilion to meet the innovators behind Sweden’s life science companies.
Evolving Landscape of Global Healthcare Partnerships
Kristel Sauter talks about the connection dynamics in BIO-International 2026, as a global gathering point and shares insights on the latest acquisitions trends and partnership potential.
Modelling the future of Biotech Operations
Biotech’s future won’t be won by a single business model. In this editorial, Anders Månsson breaks down the strengths and weaknesses of asset, platform, and service models—and argues that the real winners will be hybrids that blend all three to stay financeable, scalable, and resilient in tougher markets.